Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021.
DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharma (Flamel Technologies S.A. Acquired Avadel) (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021.
To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 6187211. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292
